{"success":true,"data":{"pressRelease":{"id":"179055","rtpr_id":"nWkrb47n2C-20261026","ticker":"NXTCL","exchange":"Nasdaq Stockholm","all_tickers":["NXTCL"],"title":"NextCell reports encouraging numerical results in younger children - strategy for adults remains unchanged","author":"Cision","published_at":"2026-10-26T06:45:13.360Z","article_body":"NextCell Pharma AB\nNextCell Pharma AB (publ) (\"NextCell\" or the \"Company\") today announces the\n12-month results from ProTrans-Young. In the predefined age group of 7-11\nyears, children treated with NXTCL-T1D had, on average, preserved a greater\nproportion of their endogenous insulin production after 12 months and\nexperienced a smaller increase in insulin requirements compared with those\nreceiving placebo. The study did not meet its primary efficacy endpoint in the\noverall study population. A preliminary analysis of 24-month data from the\nolder age group shows no clear treatment effect, although the data have not\nyet been fully analysed or validated. NextCell's commercialisation strategy\nfor adults remains unchanged, while the Company intends to refine its\ntreatment strategy for children and adolescents, focusing on treatment timing\nand the number of administrations. Further analyses are also planned to\ninvestigate how age and individual disease progression may influence treatment\nresponse.\n\n“In the younger children, we see a consistent numerical trend in favour of\ntreatment, both in terms of preserved endogenous insulin production and\ninsulin requirements. Although the differences are not statistically\nsignificant, the findings are encouraging and support further investigation of\nthe treatment’s potential in younger children. We now need to explore\nwhether children and adolescents would benefit from treatment earlier in the\ndisease course or from repeated administrations. For adults, our strategy\nremains unchanged: a single infusion within two years of diagnosis, with the\naim of preserving endogenous insulin production for many years,” says\nMathias Svahn, CEO of NextCell Pharma.\n\nNumerically favourable results in children aged 7–11 years\nProTrans-Young evaluates NextCell’s cell therapy candidate NXTCL-T1D\n(formerly ProTrans) in children and adolescents with newly diagnosed type 1\ndiabetes. The randomised part of the study enrolled 60 patients, with 15\npatients in each treatment arm within the 7–11 and 12–21-year age groups,\nrespectively.\n\nPreliminary 12-month results for the 12–21-year age group were announced in\nApril 2025 and showed no clear difference between treatment and placebo. The\ncurrent announcement provides the 12-month results for the younger age group\nand the combined analysis of both age groups.\n\nAfter 12 months, children aged 7–11 years treated with NXTCL-T1D had, on\naverage, retained 64 per cent of their baseline endogenous insulin\nproduction, compared with 51 per cent in the placebo group. Peak C-peptide\nproduction and changes in daily insulin requirements also showed numerical\ndifferences favouring NXTCL-T1D. These findings are descriptive, and no\nstatistically significant treatment effect has been demonstrated.\n\nEfficacy measures at 12 months, children aged 7–11 years     NXTCL-T1D \n    Placebo\nPreserved endogenous insulin production (C-peptide-AUC) *        64 % \n                51 %\nIncrease in daily insulin requirement                           \n                  +0,15 units/kg    +0,24 units/kg\n*The percentages for preserved insulin production represent the mean of the\nindividual patients\npercentages of baseline C-peptide AUC retained at 12 months.\n\nIn the overall study population, the adjusted treatment difference in\nC-peptide AUC was +0.0426 AUC units (95% confidence interval −0.0722 to\n+0.1574; p=0.46). In the descriptive analysis, patients treated with NXTCL-T1D\nhad, on average, retained 69 per cent of their baseline endogenous insulin\nproduction after 12 months, compared with 62 per cent in the placebo group.\nThe primary statistical analysis included 55 patients and was adjusted for\nbaseline C-peptide and age group. The difference was not statistically\nsignificant.\n\nThe adjusted treatment difference was also numerically positive at six months\nand remained similar in sensitivity analyses addressing missing data. None of\nthe secondary efficacy endpoints analysed showed statistically significant\ntreatment differences in the overall study population.\n\nIn the younger age group, 12-month data were unavailable for four of the 15\npatients in the treatment group, whereas data were available for all 15\npatients in the placebo group. This limits the conclusions that can be drawn\nfrom the numerically favourable differences. Additional sensitivity analyses\naddressing missing data were conducted for the overall study population and\ncontinued to yield numerically positive treatment effect estimates. However,\nthese analyses do not establish a treatment effect specifically in the younger\nage group.\n\nPreliminary 24-month follow-up in the older age group\nNextCell has also conducted a preliminary review of 24-month data from\npatients aged 12–21 years. The initial analysis shows no clear difference in\nthe preservation of endogenous insulin production between the treatment and\nplacebo groups, consistent with the previously announced 12-month results for\nthis age group.\n\nThe dataset has not yet been fully analysed or validated. NextCell plans to\nconduct further exploratory analyses of individual treatment responses,\nconsidering factors such as age and residual insulin production at baseline.\n\nOne potential approach is to compare patients’ observed C-peptide levels\nwith those expected based on their individual characteristics and the\nanticipated course of the disease. Such analyses may help identify patterns\nthat are not apparent from group averages and inform the design of future\nstudies. They do not, however, replace the study’s prespecified primary\nanalysis. NextCell intends to report the full 24-month results once the\nanalyses have been completed.\n\nStrategy for adults remains unchanged – long-term data support the path\ntowards marketing authorisation\nNextCell’s strategy remains to commercialise NXTCL-T1D as a single-infusion\ntreatment for adults with residual endogenous insulin production who are\nwithin two years of diagnosis. This approach is supported by the published\nrandomised adult study, which demonstrated a statistically significant\ndifference in preserved C-peptide production after 12 months.\n\nPreviously reported long-term data from the adult studies show that the\ndifference between treated patients and placebo has persisted over several\nyears and was greater at five years than after the first year. After five\nyears, treated patients had, on average, retained 57 per cent of their\nbaseline endogenous insulin production, compared with 15 per cent in the\nplacebo group. The corresponding figures after one year were 89 and 53 per\ncent, respectively.\n\nThe results now reported for children aged 7–11 years cover the first 12\nmonths following treatment. The long-term adult data provide a scientific\nrationale for investigating whether the numerically favourable differences\nobserved in younger children persist or become more pronounced with longer\nfollow-up. However, a similar pattern has not yet been demonstrated in\nchildren.\n\nFurther development of the pediatric programme – focus on disease stage and\ntreatment intensity\nNewly diagnosed type 1 diabetes in children and adolescents is characterised\nby considerable biological heterogeneity. The date of diagnosis marks when the\ndisease is detected, rather than when the autoimmune process began.\nConsequently, patients may have different levels of residual endogenous\ninsulin production and be at different stages of disease progression at\ndiagnosis. The remission phase, subsequent decline in insulin production and\nbiological maturation also vary between individuals.\n\nThe challenges of evaluating disease-modifying therapies for type 1 diabetes\nare discussed in a recent scientific article published in the journal\nDiabetes. The authors highlight age and residual C-peptide production at\ntreatment initiation as important factors influencing subsequent disease\nprogression. More precise patient selection, better characterisation of\ndisease stage and appropriately designed clinical trials may therefore improve\nthe evaluation of new therapies.\n\nFor comparison, the Phase III PROTECT trial of teplizumab included 328\nchildren and adolescents. Patients in the active treatment group received two\ncourses of treatment, with the primary efficacy endpoint assessed at 78 weeks.\nThe trial demonstrated a statistically significant difference in preserved\nC-peptide production. Although the studies are not directly comparable, they\nillustrate differences in patient numbers, treatment regimens and follow-up\nduration between clinical development programmes.\n\nBased on the ProTrans-Young results, NextCell intends to work with clinical\nexperts to assess the optimal timing of treatment in children and whether\nrepeated administrations could improve the preservation of endogenous insulin\nproduction. This work builds on the Company’s experience with both single\nand repeated administrations in adult clinical studies, as well as the\nfavourable safety profile observed to date for NXTCL-T1D. No treatment-related\nserious adverse events have been reported in the clinical studies.\n\nA further important question is why disease progression, and treatment\noutcomes vary between patients. Research conducted through the international\nTrialNet network has demonstrated that individual C-peptide outcomes can be\nassessed against expected disease progression, considering factors such as\npatient age and baseline insulin production. NextCell intends to investigate\nwhether such exploratory analyses could provide additional insights into which\npatient populations and treatment approaches should be prioritised in future\nstudies.\n\nNextCell has also discussed the potential role of screening children and\nadolescents with leading researchers and clinicians in type 1 diabetes.\nScreening can identify early stages of the disease before clinical symptoms\ndevelop, potentially enabling disease-modifying therapies to be investigated\nearlier in the disease course.\n\nThe Company therefore intends to assess the feasibility of future studies\ninvolving children identified through screening and treated before clinical\nonset. This represents a potential future direction for clinical development.\nNXTCL-T1D has not yet been investigated in these earlier stages of the\ndisease.\n\nAbout ProTrans-Young\nProTrans-Young is an investigator-initiated clinical trial sponsored by\nUppsala University, with Professor Per-Ola Carlsson as Principal Investigator.\nThe randomised part of the trial enrolled 60 children and adolescents aged\n7–21 years with newly diagnosed type 1 diabetes and evaluates NXTCL-T1D\nagainst placebo. NXTCL-T1D is an investigational cell therapy based on\nallogeneic mesenchymal stromal cells, being developed with the aim of\npreserving patients’ endogenous insulin production.\n\nThis information is the information that NextCell Pharma AB is required to\ndisclose under the EU Market Abuse Regulation. The information was provided by\nthe below contact person for publication, on October 26, 2026, about 07:45 AM\nCET.\n\nFor more information, please contact:\nMathias Svahn, CEO\nEric Gustafsson, CFO\nTel: +46 (0)8-735 55 95\nE-mail: info@nextcellpharma.com\nWebsite:: www.nextcellpharma.com\nLinkedIn: https://www.linkedin.com/company/15255207/\nTwitter: https://twitter.com/NextCellPharma\n\nCertified Adviser\nThe company's shares are listed on the Nasdaq First North Growth Market.\nRedEye Nordic Growth AB is the company´s Certified Adviser.\n\nAbout NextCell Pharma AB\nNextCell is a clinical-stage cell therapy company developing the proprietary\nNXTCL™ platform for the treatment of immune-mediated diseases, with a\nprimary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic\ncell therapies with controlled immunomodulation, consistent potency and\nscalable manufacturing. The company’s lead program in type 1 diabetes has\nshown potential to preserve insulin production and slow disease progression\nfor several years after a single treatment. The group also includes the wholly\nowned subsidiaries NextCell Sverige, NextCell Hong Kong, Cellaviva and\nQVance. The company was founded in 2014 and is headquartered in Huddinge next\nto the Karolinska University Hospital.\n\nhttps://news.cision.com/nextcell-pharma-ab/r/nextcell-reports-encouraging-numerical-results-in-younger-children---strategy-for-adults-remains-unc%2Cc4414952\n\n2026-10-26 PROTRANS YOUNG ENG\n(https://mb.cision.com/Main/15834/4414952/4337770.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkrb47n2C-20261026","title":"NextCell reports encouraging numerical results in younger children - strategy for adults remains unchanged","author":"Cision","ticker":"NXTCL","created":"2026-10-26T06:45:13.360Z","tickers":["NXTCL"],"exchange":"Nasdaq Stockholm","article_body":"NextCell Pharma AB\nNextCell Pharma AB (publ) (\"NextCell\" or the \"Company\") today announces the\n12-month results from ProTrans-Young. In the predefined age group of 7-11\nyears, children treated with NXTCL-T1D had, on average, preserved a greater\nproportion of their endogenous insulin production after 12 months and\nexperienced a smaller increase in insulin requirements compared with those\nreceiving placebo. The study did not meet its primary efficacy endpoint in the\noverall study population. A preliminary analysis of 24-month data from the\nolder age group shows no clear treatment effect, although the data have not\nyet been fully analysed or validated. NextCell's commercialisation strategy\nfor adults remains unchanged, while the Company intends to refine its\ntreatment strategy for children and adolescents, focusing on treatment timing\nand the number of administrations. Further analyses are also planned to\ninvestigate how age and individual disease progression may influence treatment\nresponse.\n\n“In the younger children, we see a consistent numerical trend in favour of\ntreatment, both in terms of preserved endogenous insulin production and\ninsulin requirements. Although the differences are not statistically\nsignificant, the findings are encouraging and support further investigation of\nthe treatment’s potential in younger children. We now need to explore\nwhether children and adolescents would benefit from treatment earlier in the\ndisease course or from repeated administrations. For adults, our strategy\nremains unchanged: a single infusion within two years of diagnosis, with the\naim of preserving endogenous insulin production for many years,” says\nMathias Svahn, CEO of NextCell Pharma.\n\nNumerically favourable results in children aged 7–11 years\nProTrans-Young evaluates NextCell’s cell therapy candidate NXTCL-T1D\n(formerly ProTrans) in children and adolescents with newly diagnosed type 1\ndiabetes. The randomised part of the study enrolled 60 patients, with 15\npatients in each treatment arm within the 7–11 and 12–21-year age groups,\nrespectively.\n\nPreliminary 12-month results for the 12–21-year age group were announced in\nApril 2025 and showed no clear difference between treatment and placebo. The\ncurrent announcement provides the 12-month results for the younger age group\nand the combined analysis of both age groups.\n\nAfter 12 months, children aged 7–11 years treated with NXTCL-T1D had, on\naverage, retained 64 per cent of their baseline endogenous insulin\nproduction, compared with 51 per cent in the placebo group. Peak C-peptide\nproduction and changes in daily insulin requirements also showed numerical\ndifferences favouring NXTCL-T1D. These findings are descriptive, and no\nstatistically significant treatment effect has been demonstrated.\n\nEfficacy measures at 12 months, children aged 7–11 years     NXTCL-T1D \n    Placebo\nPreserved endogenous insulin production (C-peptide-AUC) *        64 % \n                51 %\nIncrease in daily insulin requirement                           \n                  +0,15 units/kg    +0,24 units/kg\n*The percentages for preserved insulin production represent the mean of the\nindividual patients\npercentages of baseline C-peptide AUC retained at 12 months.\n\nIn the overall study population, the adjusted treatment difference in\nC-peptide AUC was +0.0426 AUC units (95% confidence interval −0.0722 to\n+0.1574; p=0.46). In the descriptive analysis, patients treated with NXTCL-T1D\nhad, on average, retained 69 per cent of their baseline endogenous insulin\nproduction after 12 months, compared with 62 per cent in the placebo group.\nThe primary statistical analysis included 55 patients and was adjusted for\nbaseline C-peptide and age group. The difference was not statistically\nsignificant.\n\nThe adjusted treatment difference was also numerically positive at six months\nand remained similar in sensitivity analyses addressing missing data. None of\nthe secondary efficacy endpoints analysed showed statistically significant\ntreatment differences in the overall study population.\n\nIn the younger age group, 12-month data were unavailable for four of the 15\npatients in the treatment group, whereas data were available for all 15\npatients in the placebo group. This limits the conclusions that can be drawn\nfrom the numerically favourable differences. Additional sensitivity analyses\naddressing missing data were conducted for the overall study population and\ncontinued to yield numerically positive treatment effect estimates. However,\nthese analyses do not establish a treatment effect specifically in the younger\nage group.\n\nPreliminary 24-month follow-up in the older age group\nNextCell has also conducted a preliminary review of 24-month data from\npatients aged 12–21 years. The initial analysis shows no clear difference in\nthe preservation of endogenous insulin production between the treatment and\nplacebo groups, consistent with the previously announced 12-month results for\nthis age group.\n\nThe dataset has not yet been fully analysed or validated. NextCell plans to\nconduct further exploratory analyses of individual treatment responses,\nconsidering factors such as age and residual insulin production at baseline.\n\nOne potential approach is to compare patients’ observed C-peptide levels\nwith those expected based on their individual characteristics and the\nanticipated course of the disease. Such analyses may help identify patterns\nthat are not apparent from group averages and inform the design of future\nstudies. They do not, however, replace the study’s prespecified primary\nanalysis. NextCell intends to report the full 24-month results once the\nanalyses have been completed.\n\nStrategy for adults remains unchanged – long-term data support the path\ntowards marketing authorisation\nNextCell’s strategy remains to commercialise NXTCL-T1D as a single-infusion\ntreatment for adults with residual endogenous insulin production who are\nwithin two years of diagnosis. This approach is supported by the published\nrandomised adult study, which demonstrated a statistically significant\ndifference in preserved C-peptide production after 12 months.\n\nPreviously reported long-term data from the adult studies show that the\ndifference between treated patients and placebo has persisted over several\nyears and was greater at five years than after the first year. After five\nyears, treated patients had, on average, retained 57 per cent of their\nbaseline endogenous insulin production, compared with 15 per cent in the\nplacebo group. The corresponding figures after one year were 89 and 53 per\ncent, respectively.\n\nThe results now reported for children aged 7–11 years cover the first 12\nmonths following treatment. The long-term adult data provide a scientific\nrationale for investigating whether the numerically favourable differences\nobserved in younger children persist or become more pronounced with longer\nfollow-up. However, a similar pattern has not yet been demonstrated in\nchildren.\n\nFurther development of the pediatric programme – focus on disease stage and\ntreatment intensity\nNewly diagnosed type 1 diabetes in children and adolescents is characterised\nby considerable biological heterogeneity. The date of diagnosis marks when the\ndisease is detected, rather than when the autoimmune process began.\nConsequently, patients may have different levels of residual endogenous\ninsulin production and be at different stages of disease progression at\ndiagnosis. The remission phase, subsequent decline in insulin production and\nbiological maturation also vary between individuals.\n\nThe challenges of evaluating disease-modifying therapies for type 1 diabetes\nare discussed in a recent scientific article published in the journal\nDiabetes. The authors highlight age and residual C-peptide production at\ntreatment initiation as important factors influencing subsequent disease\nprogression. More precise patient selection, better characterisation of\ndisease stage and appropriately designed clinical trials may therefore improve\nthe evaluation of new therapies.\n\nFor comparison, the Phase III PROTECT trial of teplizumab included 328\nchildren and adolescents. Patients in the active treatment group received two\ncourses of treatment, with the primary efficacy endpoint assessed at 78 weeks.\nThe trial demonstrated a statistically significant difference in preserved\nC-peptide production. Although the studies are not directly comparable, they\nillustrate differences in patient numbers, treatment regimens and follow-up\nduration between clinical development programmes.\n\nBased on the ProTrans-Young results, NextCell intends to work with clinical\nexperts to assess the optimal timing of treatment in children and whether\nrepeated administrations could improve the preservation of endogenous insulin\nproduction. This work builds on the Company’s experience with both single\nand repeated administrations in adult clinical studies, as well as the\nfavourable safety profile observed to date for NXTCL-T1D. No treatment-related\nserious adverse events have been reported in the clinical studies.\n\nA further important question is why disease progression, and treatment\noutcomes vary between patients. Research conducted through the international\nTrialNet network has demonstrated that individual C-peptide outcomes can be\nassessed against expected disease progression, considering factors such as\npatient age and baseline insulin production. NextCell intends to investigate\nwhether such exploratory analyses could provide additional insights into which\npatient populations and treatment approaches should be prioritised in future\nstudies.\n\nNextCell has also discussed the potential role of screening children and\nadolescents with leading researchers and clinicians in type 1 diabetes.\nScreening can identify early stages of the disease before clinical symptoms\ndevelop, potentially enabling disease-modifying therapies to be investigated\nearlier in the disease course.\n\nThe Company therefore intends to assess the feasibility of future studies\ninvolving children identified through screening and treated before clinical\nonset. This represents a potential future direction for clinical development.\nNXTCL-T1D has not yet been investigated in these earlier stages of the\ndisease.\n\nAbout ProTrans-Young\nProTrans-Young is an investigator-initiated clinical trial sponsored by\nUppsala University, with Professor Per-Ola Carlsson as Principal Investigator.\nThe randomised part of the trial enrolled 60 children and adolescents aged\n7–21 years with newly diagnosed type 1 diabetes and evaluates NXTCL-T1D\nagainst placebo. NXTCL-T1D is an investigational cell therapy based on\nallogeneic mesenchymal stromal cells, being developed with the aim of\npreserving patients’ endogenous insulin production.\n\nThis information is the information that NextCell Pharma AB is required to\ndisclose under the EU Market Abuse Regulation. The information was provided by\nthe below contact person for publication, on October 26, 2026, about 07:45 AM\nCET.\n\nFor more information, please contact:\nMathias Svahn, CEO\nEric Gustafsson, CFO\nTel: +46 (0)8-735 55 95\nE-mail: info@nextcellpharma.com\nWebsite:: www.nextcellpharma.com\nLinkedIn: https://www.linkedin.com/company/15255207/\nTwitter: https://twitter.com/NextCellPharma\n\nCertified Adviser\nThe company's shares are listed on the Nasdaq First North Growth Market.\nRedEye Nordic Growth AB is the company´s Certified Adviser.\n\nAbout NextCell Pharma AB\nNextCell is a clinical-stage cell therapy company developing the proprietary\nNXTCL™ platform for the treatment of immune-mediated diseases, with a\nprimary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic\ncell therapies with controlled immunomodulation, consistent potency and\nscalable manufacturing. The company’s lead program in type 1 diabetes has\nshown potential to preserve insulin production and slow disease progression\nfor several years after a single treatment. The group also includes the wholly\nowned subsidiaries NextCell Sverige, NextCell Hong Kong, Cellaviva and\nQVance. The company was founded in 2014 and is headquartered in Huddinge next\nto the Karolinska University Hospital.\n\nhttps://news.cision.com/nextcell-pharma-ab/r/nextcell-reports-encouraging-numerical-results-in-younger-children---strategy-for-adults-remains-unc%2Cc4414952\n\n2026-10-26 PROTRANS YOUNG ENG\n(https://mb.cision.com/Main/15834/4414952/4337770.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-10-26T06:45:13.469224681Z","server_sent_at_ms":1792997113469},"received_at":"2026-10-26T06:45:13.536Z","source_url":"https://news.cision.com/nextcell-pharma-ab/r/nextcell-reports-encouraging-numerical-results-in-younger-children---strategy-for-adults-remains-unc%2Cc4414952"},"analysis":{"id":"166951","press_release_id":"179055","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["primary efficacy endpoint missed in overall study population (p=0.46)","favorable 7-11 subgroup result based on incomplete data (missing 12-month data for 4 of 15 treated patients)","no clear treatment effect in adolescents at 12 or preliminary 24 months","favorable pediatric signal is descriptive only and could be confounded by disease heterogeneity"],"eventType":"clinical_trial","narrative":"NextCell Pharma's ProTrans-Young trial of NXTCL-T1D in children with newly diagnosed type 1 diabetes missed its primary efficacy endpoint in the overall population (adjusted difference +0.0426 AUC units, p=0.46).\n\nIn the predefined 7-11 age group, treated children retained 64% of baseline insulin production versus 51% on placebo, but differences were not statistically significant and 12-month data were missing for four of 15 treated patients.\n\nPreliminary 24-month data in the 12-21 age group show no clear treatment effect, consistent with earlier 12-month results. The company plans to refine the pediatric strategy around treatment timing, repeated dosing, and screening, while its commercialization strategy for adults remains unchanged and is supported by statistically significant long-term adult data.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Primary endpoint miss in pediatrics, but a consistent 64%-vs-51% C-peptide signal in younger children keeps the program alive while the adult strategy stays intact."},"keyFigures":{"drugName":"NXTCL-T1D (formerly ProTrans)","phaseOfTrial":"randomized Phase 2 (investigator-initiated)","customDimensions":{"enrolled_patients":60,"primary_endpoint_met":false,"primary_analysis_p_value":0.46,"primary_analysis_patients":55,"adult_5yr_retention_placebo":"15%","adult_5yr_retention_treated":"57%","c_peptide_retention_7_11_placebo":"51%","c_peptide_retention_7_11_treated":"64%","c_peptide_retention_overall_placebo":"62%","c_peptide_retention_overall_treated":"69%","insulin_requirement_increase_placebo":"+0.24 units/kg","insulin_requirement_increase_treated":"+0.15 units/kg"}},"quotedText":"Although the differences are not statistically significant, the findings are encouraging and support further investigation of the treatment's potential in younger children.","namedEntities":{"people":[{"name":"Mathias Svahn","role":"CEO"},{"name":"Eric Gustafsson","role":"CFO"},{"name":"Per-Ola Carlsson","role":"Principal Investigator, ProTrans-Young"}],"products":["NXTCL-T1D","ProTrans","NXTCL platform"],"companies":[{"name":"NextCell Pharma AB","ticker":"NXTCL"},{"name":"Uppsala University","relationship":"trial sponsor"},{"name":"RedEye Nordic Growth AB","relationship":"certified adviser"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The Phase II ProTrans-Young trial missed its primary efficacy endpoint in the overall population (p=0.46), a negative for the pediatric program, though numerically favorable trends in children 7-11 and an unchanged adult commercialization strategy soften the blow."},"tickerRelevance":{"others":[],"primary":"NXTCL"},"globalImportance":30,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"listVenue":"Nasdaq First North Growth Market","tickerTier":"small-cap","eventGravity":"primary-endpoint-miss-with-positive-subgroup","householdBrandBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"mixed","material_impact_score":3,"narrative":"NextCell Pharma's ProTrans-Young trial of NXTCL-T1D in children with newly diagnosed type 1 diabetes missed its primary efficacy endpoint in the overall population (adjusted difference +0.0426 AUC units, p=0.46).\n\nIn the predefined 7-11 age group, treated children retained 64% of baseline insulin production versus 51% on placebo, but differences were not statistically significant and 12-month data were missing for four of 15 treated patients.\n\nPreliminary 24-month data in the 12-21 age group show no clear treatment effect, consistent with earlier 12-month results. The company plans to refine the pediatric strategy around treatment timing, repeated dosing, and screening, while its commercialization strategy for adults remains unchanged and is supported by statistically significant long-term adult data.","key_figures":{"drugName":"NXTCL-T1D (formerly ProTrans)","phaseOfTrial":"randomized Phase 2 (investigator-initiated)","customDimensions":{"enrolled_patients":60,"primary_endpoint_met":false,"primary_analysis_p_value":0.46,"primary_analysis_patients":55,"adult_5yr_retention_placebo":"15%","adult_5yr_retention_treated":"57%","c_peptide_retention_7_11_placebo":"51%","c_peptide_retention_7_11_treated":"64%","c_peptide_retention_overall_placebo":"62%","c_peptide_retention_overall_treated":"69%","insulin_requirement_increase_placebo":"+0.24 units/kg","insulin_requirement_increase_treated":"+0.15 units/kg"}},"named_entities":{"people":[{"name":"Mathias Svahn","role":"CEO"},{"name":"Eric Gustafsson","role":"CFO"},{"name":"Per-Ola Carlsson","role":"Principal Investigator, ProTrans-Young"}],"products":["NXTCL-T1D","ProTrans","NXTCL platform"],"companies":[{"name":"NextCell Pharma AB","ticker":"NXTCL"},{"name":"Uppsala University","relationship":"trial sponsor"},{"name":"RedEye Nordic Growth AB","relationship":"certified adviser"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-26T06:45:23.066Z","global_importance":30,"audience_relevance":20,"importance_components":{"listVenue":"Nasdaq First North Growth Market","tickerTier":"small-cap","eventGravity":"primary-endpoint-miss-with-positive-subgroup","householdBrandBoost":0}},"durationMs":7484,"modelName":"glm-5.3-flashx"}}